Scribe Therapeutics, Inc. (SCTX) stock soared 66.67% during its intraday trading debut on Friday, following the pricing of its upsized initial public offering at the top of its expected range. The clinical-stage biotechnology company sold 8.58 million shares at $15 per share, raising $128.7 million, which exceeded its initial plan to offer 7.15 million shares between $13 and $15.

The robust investor demand for the CRISPR gene-editing company, co-founded by Nobel laureate Jennifer Doudna, reflects strong market confidence in its epigenetic silencing technology platform and its lead cardiovascular drug candidate, STX-1150. The successful offering also gained significant backing from strategic partners, with French pharmaceutical giant Sanofi concurrently purchasing 500,000 shares through a private placement, and existing investor Eli Lilly indicating its intention to increase its stake to maintain an ownership level of up to roughly 11%.

The strong debut comes amid a broader recovery in the biotech IPO market in 2026, where the sector has posted a weighted average return of 55%, significantly outperforming other areas such as AI-related listings. Scribe's upsized and top-priced IPO highlights the heightened investor appetite for platform biotechnology companies with clear clinical pathways and large addressable markets.